


Product Sheet

LDN-193189, ALK-2, -3 Inhibitor

Catalog #	LDN-002; LDN-010; LDN-050
Description	<p>A selective inhibitor of bone morphogenetic protein (BMP) type I receptors (ALK-2 and ALK-3). Only weakly inhibits ALK-4, -5, and -7.</p> <p>4-[6-(4-Piperazin-1-yl-phenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline</p> <p><i>Ref: Cuny, G.D., et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett 18: 4388-92, 2008.</i></p>
Formulation	Powder
Reconstitution	Before reconstitution, we recommend a brief spin to drive down any material dislodged from the bottom of the tube. The compound is soluble in DMSO.
Stability	The powder is stable for at least 2 year if stored at -20 degree C. The dissolved compound is stable for at least 1 month at 4 degree C, but should be stored in aliquots at -20 degree C for longer term. Protect from light.
Purity	Greater than 98% as determined by LC/MS analysis. LC/MS and/or NMR data available upon request.
Biological Activity	Not determined.

Structural Info



MW: 406.48

Formula: C₂₅H₂₂N₆

Solubility: Soluble in DMSO at 10 mM.

CAS: 1062368-24-4

For Research Use Only. Not for Use in Humans.